Eli Lilly (LLY) Canada Inc. said it is disappointed and strongly disagrees with Canada’s Drug Agency’s Final Recommendation for Ebglyss, published on Friday, November 15, 2024. The CDA-AMC recommended ...
The reason for the disappointing sales, according to the company, is not an issue of demand or supply. During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting ...
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback